Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in a Rare Disease.

P3 (range 12.7%–28.9%, at baseline 13.5%) showed a trend to increased acanthocyte levels under treatment and subsequent decrease after dasatinib withdrawal ( Figure 3 A).

also in 53,322 other papers